Skip to main
CLYM

CLYM Stock Forecast & Price Target

CLYM Analyst Ratings

Based on 13 analyst ratings
Strong Buy
Strong Buy 62%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Climb Bio is a promising biotechnology company with a positive outlook due to its pipeline of potential therapeutics for immune-mediated diseases and a favorable safety profile demonstrated by its lead drug candidates, Budoprutug and CLYM116. Additionally, the company's financial outlook is strong, with enough cash to fund operations until 2028 and potential for strong sales of its drugs in multiple indications. However, there are potential financial and competition risks that could impact the company's future performance.

Bears say

Climb Bio is a clinical-stage biotechnology company with a focus on developing therapies for immune-mediated diseases, including Budoprutug for various B-cell mediated diseases and CLYM116 for IgA nephropathy. However, their pipeline drugs have exhibited mixed results in clinical trials, with the efficacy of CLYM116 being unclear and the potential for adverse effects such as immunogenicity remaining unresolved. Additionally, the company's accelerated approval pathway for Budoprutug may not be a guarantee and trial sequencing in China may limit the applicability of results to global markets. Overall, Climb Bio has yet to prove the efficacy and safety of their pipeline drugs, raising concerns about their long-term potential and leading to a negative outlook for the company's stock.

CLYM has been analyzed by 13 analysts, with a consensus rating of Strong Buy. 62% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Climb Bio Inc (CLYM) Forecast

Analysts have given CLYM a Strong Buy based on their latest research and market trends.

According to 13 analysts, CLYM has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Climb Bio Inc (CLYM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.